Peripheral T Cell Lymphoma Clinical Trial
Official title:
A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05559008 -
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06083701 -
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02856997 -
Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04083495 -
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT05979792 -
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
|
Early Phase 1 | |
| Recruiting |
NCT04984837 -
Study of Lacutamab in Peripheral T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06072131 -
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
|
Phase 3 | |
| Completed |
NCT01716806 -
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
|
Phase 2 | |
| Terminated |
NCT03947255 -
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04028440 -
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
|
Early Phase 1 | |
| Not yet recruiting |
NCT05923502 -
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
|
||
| Recruiting |
NCT05883449 -
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
|
Phase 2 | |
| Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03586999 -
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04489264 -
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
|
||
| Recruiting |
NCT06151106 -
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT02753543 -
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06089941 -
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
|